Literature DB >> 18278130

[PTCH2 gene alterations in keratocystic odontogenic tumors associated with nevoid basal cell carcinoma syndrome].

Li-Li Xu1, Tie-Jun Li.   

Abstract

OBJECTIVE: To investigate alterations in PTCH2 in keratocystic odontogenic tumors (KCOT) associated with nevoid basal cell carcinoma syndrome (NBCCS).
METHODS: Genomic DNA was extracted from samples of frozen lesion tissues and peripheral blood of 15 NBCCS patients with multiple KCOTs. PTCH2 mutations were detected by PCR-direct sequencing.
RESULTS: 2 novel missence mutations(c.323 T>C,c.1319 C>T)of PTCH2 were identified and 9 polymorphisms (3 of which were novel) were determined in the present series.
CONCLUSION: Although not as frequent as PTCH1 mutations, PTCH2 germline mutations were detectable in a subset of NBCCS patients with KCOTs. The pathogenetic role of these PTCH2 mutations is yet to be clarified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278130

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  4 in total

1.  Update on Odontogenic Tumors: Proceedings of the North American Head and Neck Pathology Society.

Authors:  Elizabeth Ann Bilodeau; Raja R Seethala
Journal:  Head Neck Pathol       Date:  2019-03-18

2.  PTCH2 is not a strong candidate gene for gorlin syndrome predisposition.

Authors:  Miriam J Smith; D Gareth Evans
Journal:  Fam Cancer       Date:  2021-06-25       Impact factor: 2.446

3.  Bioinformatics Analysis Reveals Genes Involved in the Pathogenesis of Ameloblastoma and Keratocystic Odontogenic Tumor.

Authors:  Eliane Macedo Sobrinho Santos; Hércules Otacílio Santos; Ivoneth Dos Santos Dias; Sérgio Henrique Santos; Alfredo Maurício Batista de Paula; John David Feltenberger; André Luiz Sena Guimarães; Lucyana Conceição Farias
Journal:  Int J Mol Cell Med       Date:  2016-12-06

4.  Multidisciplinary oral rehabilitation of an adolescent suffering from juvenile Gorlin-Goltz syndrome - a case report.

Authors:  Manfred Nilius; Jürgen Kohlhase; Johann Lorenzen; Günter Lauer; Matthias C Schulz
Journal:  Head Face Med       Date:  2019-02-08       Impact factor: 2.151

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.